TransPharma Announces Successful Completion of Phase 2 Trial of ViaDerm-hPTH(1-34)
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
TransPharma Medical Ltd. has announced the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.
In June 2008, Eli Lilly and Company and TransPharma entered a licensing and development agreement relating to TransPharma’s ViaDerm-hPTH(1-34) product for the treatment of severe osteoporosis. As part of this project, TransPharma has completed a three-month Phase 2A trial for transdermal PTH(1-34).
The primary and secondary endpoints for efficacy and safety were met. The safety endpoints included a skin safety endpoint for repeated dosing with the ViaDerm system.
More details of the phase 2A study results are expected to be shared during 2010 in one of the leading Osteoporosis conferences. Initiation of a dose-ranging Phase 2B study to be jointly conducted by Eli Lilly and TransPharma is planned for later this year.
"We are very pleased with the results of this trial, which demonstrate remarkable progress in the use of the ViaDerm system in clinical trials," said Dr. Daphna Heffetz, CEO of TransPharma Medical.
"We have met the primary and secondary endpoints of the phase 2A trial. We are looking forward to the Phase 2B trial, and hope that, in the future, we will be able to improve therapy for people suffering from osteoporosis by offering an alternative to daily injection of PTH.”
In June 2008, Eli Lilly and Company and TransPharma entered a licensing and development agreement relating to TransPharma’s ViaDerm-hPTH(1-34) product for the treatment of severe osteoporosis. As part of this project, TransPharma has completed a three-month Phase 2A trial for transdermal PTH(1-34).
The primary and secondary endpoints for efficacy and safety were met. The safety endpoints included a skin safety endpoint for repeated dosing with the ViaDerm system.
More details of the phase 2A study results are expected to be shared during 2010 in one of the leading Osteoporosis conferences. Initiation of a dose-ranging Phase 2B study to be jointly conducted by Eli Lilly and TransPharma is planned for later this year.
"We are very pleased with the results of this trial, which demonstrate remarkable progress in the use of the ViaDerm system in clinical trials," said Dr. Daphna Heffetz, CEO of TransPharma Medical.
"We have met the primary and secondary endpoints of the phase 2A trial. We are looking forward to the Phase 2B trial, and hope that, in the future, we will be able to improve therapy for people suffering from osteoporosis by offering an alternative to daily injection of PTH.”
